Stock Scorecard
Stock Summary for EyePoint Pharmaceuticals Inc (EYPT) - $18.38 as of 12/24/2025 2:17:26 PM EST
Total Score
8 out of 30
Safety Score
31 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EYPT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EYPT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EYPT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for EYPT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for EYPT (31 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for EYPT
Financial Details for EYPT
Company Overview |
|
|---|---|
| Ticker | EYPT |
| Company Name | EyePoint Pharmaceuticals Inc |
| Country | N/A |
| Description | EyePoint Pharmaceuticals, Inc. is an innovative biopharmaceutical firm headquartered in Watertown, Massachusetts, focused on developing cutting-edge therapeutics for serious ocular diseases. Leveraging its proprietary micro-insert technology, EyePoint specializes in sustained-release drug delivery systems that address significant unmet medical needs in ophthalmology. The company boasts a promising pipeline aimed at treating retinal diseases, positioning itself for growth in key markets such as the United States, China, and the United Kingdom, and solidifying its role as a vital player in the evolving landscape of eye care solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/5/2026 |
Stock Price History |
|
| Last Day Price | 18.38 |
| Price 4 Years Ago | 12.24 |
| Last Day Price Updated | 12/24/2025 2:17:26 PM EST |
| Last Day Volume | 1,255,146 |
| Average Daily Volume | 1,265,274 |
| 52-Week High | 19.11 |
| 52-Week Low | 3.91 |
| Last Price to 52 Week Low | 370.08% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 65.27 |
| Sector PE | 120.50 |
| 5-Year Average PE | -5.85 |
| Free Cash Flow Ratio | 20.42 |
| Industry Free Cash Flow Ratio | 13.32 |
| Sector Free Cash Flow Ratio | 30.70 |
| Current Ratio Most Recent Quarter | 7.18 |
| Total Cash Per Share | 0.90 |
| Book Value Per Share Most Recent Quarter | 2.88 |
| Price to Book Ratio | 6.89 |
| Industry Price to Book Ratio | 61.84 |
| Sector Price to Book Ratio | 56.47 |
| Price to Sales Ratio Twelve Trailing Months | 33.36 |
| Industry Price to Sales Ratio Twelve Trailing Months | 55.64 |
| Sector Price to Sales Ratio Twelve Trailing Months | 25.45 |
| Analyst Buy Ratings | 10 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 82,787,000 |
| Market Capitalization | 1,521,625,060 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.26% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -84.86% |
| Reported EPS 12 Trailing Months | -3.00 |
| Reported EPS Past Year | -2.35 |
| Reported EPS Prior Year | -2.31 |
| Net Income Twelve Trailing Months | -205,752,000 |
| Net Income Past Year | -130,870,000 |
| Net Income Prior Year | -70,795,000 |
| Quarterly Revenue Growth YOY | -90.80% |
| 5-Year Revenue Growth | 16.27% |
| Operating Margin Twelve Trailing Months | -6,421.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 74,577,000 |
| Total Cash Past Year | 99,704,000 |
| Total Cash Prior Year | 281,263,000 |
| Net Cash Position Most Recent Quarter | 44,577,000 |
| Net Cash Position Past Year | 69,704,000 |
| Long Term Debt Past Year | 30,000,000 |
| Long Term Debt Prior Year | 30,000,000 |
| Total Debt Most Recent Quarter | 30,000,000 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 0.87 |
| Total Stockholder Equity Past Year | 336,501,000 |
| Total Stockholder Equity Prior Year | 266,323,000 |
| Total Stockholder Equity Most Recent Quarter | 200,182,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -213,590,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.58 |
| Free Cash Flow Past Year | -130,278,000 |
| Free Cash Flow Prior Year | -1,608,000 |
Options |
|
| Put/Call Ratio | 0.21 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 9.31 |
| 20-Day Bollinger Middle Band | 13.72 |
| 20-Day Bollinger Upper Band | 18.12 |
| Beta | 1.69 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 12/22/2025 10:35:43 PM EST |